Generate Investment Management Ltd Purchases 22,330 Shares of Cencora, Inc. (NYSE:COR)

Generate Investment Management Ltd increased its position in Cencora, Inc. (NYSE:COR - Free Report) by 92.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,508 shares of the company's stock after buying an additional 22,330 shares during the quarter. Generate Investment Management Ltd's holdings in Cencora were worth $10,449,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Insight Wealth Strategies LLC boosted its stake in shares of Cencora by 124.6% during the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company's stock worth $4,549,000 after acquiring an additional 11,232 shares in the last quarter. Cerity Partners LLC lifted its holdings in shares of Cencora by 10.1% during the third quarter. Cerity Partners LLC now owns 39,457 shares of the company's stock valued at $8,881,000 after purchasing an additional 3,610 shares during the last quarter. Sylvest Advisors LLC acquired a new position in shares of Cencora in the 4th quarter valued at $1,105,000. Thurston Springer Miller Herd & Titak Inc. increased its stake in Cencora by 71.1% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company's stock worth $1,583,000 after purchasing an additional 2,928 shares in the last quarter. Finally, Portfolio Design Labs LLC acquired a new stake in Cencora during the 3rd quarter worth about $1,404,000. Institutional investors own 97.52% of the company's stock.

Analyst Ratings Changes

COR has been the subject of several recent analyst reports. Mizuho initiated coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 target price for the company. Evercore ISI increased their target price on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Robert W. Baird lifted their price target on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. Wells Fargo & Company increased their price objective on Cencora from $237.00 to $251.00 and gave the stock an "equal weight" rating in a research note on Wednesday, January 29th. Finally, JPMorgan Chase & Co. lifted their target price on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $277.90.

Cencora Stock Up 0.2 %

NYSE COR traded up $0.48 during trading on Tuesday, reaching $246.86. The company's stock had a trading volume of 1,076,644 shares, compared to its average volume of 1,476,687. The business has a 50-day moving average price of $238.86 and a 200-day moving average price of $237.03. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $262.26. The stock has a market capitalization of $47.71 billion, a PE ratio of 35.11, a PEG ratio of 1.49 and a beta of 0.49. The company has a current ratio of 0.92, a quick ratio of 0.53 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, research analysts forecast that Cencora, Inc. will post 15.36 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.89%. The ex-dividend date is Friday, February 14th. Cencora's dividend payout ratio is currently 31.29%.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the sale, the chairman now owns 306,752 shares of the company's stock, valued at approximately $74,283,064.32. This trade represents a 6.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the firm's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares of the company's stock, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 73,187 shares of company stock worth $17,790,912 over the last three months. 10.80% of the stock is currently owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.